CNS Pharmaceuticals (NASDAQ:CNSP) Announces Earnings Results

CNS Pharmaceuticals (NASDAQ:CNSP) released its earnings results on Wednesday. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14), FiscalAI reports.

CNS Pharmaceuticals Stock Performance

Shares of CNSP traded down $0.34 during mid-day trading on Wednesday, hitting $5.16. The company’s stock had a trading volume of 4,285 shares, compared to its average volume of 600,610. CNS Pharmaceuticals has a one year low of $1.90 and a one year high of $10.59. The firm has a market capitalization of $7.54 million, a PE ratio of -0.17 and a beta of 3.05. The stock’s 50-day moving average is $4.96 and its two-hundred day moving average is $4.19.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CNS Pharmaceuticals has an average rating of “Hold” and a consensus target price of $20.00.

Insider Transactions at CNS Pharmaceuticals

In related news, Director Faith L. Charles bought 7,100 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were acquired at an average price of $4.79 per share, with a total value of $34,009.00. Following the completion of the transaction, the director owned 7,100 shares of the company’s stock, valued at $34,009. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.01% of the company’s stock.

Institutional Trading of CNS Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of CNSP. Boothbay Fund Management LLC bought a new position in shares of CNS Pharmaceuticals during the 4th quarter worth about $71,000. Ikarian Capital LLC acquired a new position in shares of CNS Pharmaceuticals during the fourth quarter valued at about $241,000. Finally, Armistice Capital LLC acquired a new position in shares of CNS Pharmaceuticals during the second quarter valued at about $335,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.